-
公开(公告)号:US20140314784A1
公开(公告)日:2014-10-23
申请号:US14232751
申请日:2012-07-19
申请人: Vahe Bedian , Youzhen Wang , Ian Foltz , Palaniswami Rathanaswami , Jaspal Singh Kang , Adeela Kamal , Philipp Steiner
发明人: Vahe Bedian , Youzhen Wang , Ian Foltz , Palaniswami Rathanaswami , Jaspal Singh Kang , Adeela Kamal , Philipp Steiner
IPC分类号: C07K16/28 , A61K45/06 , A61K39/395
CPC分类号: C07K16/2866 , A61K39/3955 , A61K45/06 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
摘要: The disclosure relates to antibodies or antigen binding fragments that specifically bind to CXCR4 and inhibit the biological activity of CXCR4 and uses of such agents. More specifically the disclosure relates to fully human antibodies or antigen binding fragments directed to CXCR4 that specifically bind to CXCR4 and uses of these antibodies. Aspects of the disclosure also relate to hybridomas or other cell lines expressing such antibodies. The disclosed antibodies (including antigen binding fragments) are useful as diagnostics and for the treatment of diseases associated with the activity and/or expression of CXCR4.
摘要翻译: 本公开涉及特异性结合CXCR4并抑制CXCR4的生物学活性的抗体或抗原结合片段以及这些试剂的用途。 更具体地,本公开涉及针对CXCR4的完全人抗体或抗原结合片段,其特异性结合CXCR4和这些抗体的用途。 本公开的方面还涉及表达这种抗体的杂交瘤或其它细胞系。 所公开的抗体(包括抗原结合片段)可用作诊断和治疗与CXCR4的活性和/或表达相关的疾病。
-
2.
公开(公告)号:US20100260765A1
公开(公告)日:2010-10-14
申请号:US12669724
申请日:2008-07-23
CPC分类号: C07K16/2863 , A61K38/16 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/73 , C07K2317/75 , C07K2317/76 , C07K2317/92
摘要: The invention relates to targeted binding agents against KDR and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to KDR. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of KDR and as diagnostics.
摘要翻译: 本发明涉及针对KDR的靶向结合剂及其用途。 更具体地,本发明涉及针对KDR的完全人单克隆抗体。 所描述的靶向结合剂可用于治疗与KDR的活性和/或过量产生相关的疾病和作为诊断。
-
公开(公告)号:US08119130B2
公开(公告)日:2012-02-21
申请号:US12669724
申请日:2008-07-23
IPC分类号: A61K39/395 , A61K39/00 , C12P21/08 , C07K16/00 , C07K16/28
CPC分类号: C07K16/2863 , A61K38/16 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/73 , C07K2317/75 , C07K2317/76 , C07K2317/92
摘要: The invention relates to targeted binding agents against KDR and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to KDR. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of KDR and as diagnostics.
摘要翻译: 本发明涉及针对KDR的靶向结合剂及其用途。 更具体地,本发明涉及针对KDR的完全人单克隆抗体。 所描述的靶向结合剂可用于治疗与KDR的活性和/或过量产生相关的疾病和作为诊断。
-
公开(公告)号:US20100196385A1
公开(公告)日:2010-08-05
申请号:US12562268
申请日:2009-09-18
申请人: Vahe Bedian , David Jenkins , Ian Foltz
发明人: Vahe Bedian , David Jenkins , Ian Foltz
IPC分类号: A61K39/395 , C07K16/18 , C07H21/00 , A61P35/00
CPC分类号: C07K16/28 , A61K39/395 , A61K39/39533 , A61K39/3955 , A61K2039/505 , C07H21/04 , C07K14/475 , C07K16/22 , C07K2317/565 , C07K2317/92
摘要: The invention relates to targeted binding agents against DLL4 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to DLL4. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of DLL4 and as diagnostics.
摘要翻译: 本发明涉及针对DLL4的靶向结合剂及其用途。 更具体地,本发明涉及针对DLL4的完全人单克隆抗体。 所描述的靶向结合剂可用于治疗与DLL4的活性和/或过量产生相关的疾病和作为诊断。
-
公开(公告)号:US20080057063A1
公开(公告)日:2008-03-06
申请号:US11833486
申请日:2007-08-03
申请人: Julie Rinkenberger , Ian Foltz , Avril Alfred , Simon Barry , Vahe Bedian
发明人: Julie Rinkenberger , Ian Foltz , Avril Alfred , Simon Barry , Vahe Bedian
CPC分类号: C07K16/2839 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92 , C12N5/0686 , C12N2501/998
摘要: Targeted binding agents, such antibodies directed to the antigen αVβ6 and uses of such agents are described. In particular, fully human monoclonal antibodies directed to the antigen αVβ6 are disclosed. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3 are disclosed. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also disclosed.
摘要翻译: 描述了靶向结合剂,针对抗原αVβ6的这种抗体及其用途。 特别地,公开了针对抗原αVβ6的完全人单克隆抗体。 编码的核苷酸序列和包含重链和轻链免疫球蛋白分子的氨基酸序列,特别是对应于跨越框架区和/或互补决定区(CDR)的连续重链和轻链序列的序列,特别是从FR1至FR4或CDR1至CDR3 被披露。 还公开了表达这种免疫球蛋白分子和单克隆抗体的杂交瘤或其它细胞系。
-
公开(公告)号:US07326414B2
公开(公告)日:2008-02-05
申请号:US11375221
申请日:2006-03-13
申请人: Vahe Bedian , Madhav Narasimha Devalaraja , Ian Foltz , Mary Haak-Frendscho , Sirid-Aimée Kellermann , Joseph Edwin Low , James Leslie Mobley
发明人: Vahe Bedian , Madhav Narasimha Devalaraja , Ian Foltz , Mary Haak-Frendscho , Sirid-Aimée Kellermann , Joseph Edwin Low , James Leslie Mobley
IPC分类号: A61K39/395 , C07K16/00
CPC分类号: C07K16/243 , A61K38/193 , A61K39/395 , A61K2039/505 , C07K16/24 , C07K2317/14 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , G06Q30/02 , G06Q30/0601 , G06Q40/04 , G06Q50/12 , Y02A50/412
摘要: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to a M-CSF, preferably human M-CSF, and that function to inhibit a M-CSF. The invention also relates to human anti-M-CSF antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-M-CSF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-M-CSF antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-M-CSF antibodies. The invention also relates to transgenic animals and transgenic plants comprising nucleic acid molecules of the present invention.
-
公开(公告)号:US20050059113A1
公开(公告)日:2005-03-17
申请号:US10938353
申请日:2004-09-09
申请人: Vahe Bedian , Madhav Devalaraja , Ian Foltz , Mary Haak-Frendscho , Sirid-Aimee Kellermann , Joseph Low , James Mobley
发明人: Vahe Bedian , Madhav Devalaraja , Ian Foltz , Mary Haak-Frendscho , Sirid-Aimee Kellermann , Joseph Low , James Mobley
CPC分类号: C07K16/243 , A61K38/193 , A61K39/395 , A61K2039/505 , C07K16/24 , C07K2317/14 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , G06Q30/02 , G06Q30/0601 , G06Q40/04 , G06Q50/12 , Y02A50/412
摘要: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to a M-CSF, preferably human M-CSF, and that function to inhibit a M-CSF. The invention also relates to human anti-M-CSF antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-M-CSF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-M-CSF antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-M-CSF antibodies. The invention also relates to transgenic animals and transgenic plants comprising nucleic acid molecules of the present invention.
摘要翻译: 本发明涉及特异性结合M-CSF,优选人M-CSF的抗体及其抗原结合部分,其功能是抑制M-CSF。 本发明还涉及人抗M-CSF抗体及其抗原结合部分。 本发明还涉及嵌合,双特异性,衍生的单链抗体或融合蛋白的部分的抗体。 本发明还涉及衍生自人抗M-CSF抗体的分离的重链和轻链免疫球蛋白和编码这种免疫球蛋白的核酸分子。 本发明还涉及制备人抗M-CSF抗体的方法,包含这些抗体的组合物和使用该抗体和组合物进行诊断和治疗的方法。 本发明还提供使用编码包含人抗M-CSF抗体的重和/或轻免疫球蛋白分子的核酸分子的基因治疗方法。 本发明还涉及包含本发明的核酸分子的转基因动物和转基因植物。
-
公开(公告)号:US08398975B2
公开(公告)日:2013-03-19
申请号:US12782335
申请日:2010-05-18
申请人: Julie Rinkenberger , Ian Foltz , Avril Alfred , Simon Thomas Barry , Vahe Bedian
发明人: Julie Rinkenberger , Ian Foltz , Avril Alfred , Simon Thomas Barry , Vahe Bedian
IPC分类号: A61K39/395 , C07K16/00 , C07K16/46 , C07K16/28
CPC分类号: C07K16/2839 , A61K2039/505 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92 , C12N5/0686 , C12N2501/998
摘要: Targeted binding agents, such antibodies directed to the antigen αVβ6 and uses of such agents are described. In particular, fully human monoclonal antibodies directed to the antigen αVβ6 are disclosed. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3 are disclosed. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also disclosed.
摘要翻译: 描述了靶向结合剂,针对抗原αV和bgr的这种抗体以及这些药剂的用途。 特别地,公开了针对抗原αV和bgr的完全人单克隆抗体。 编码的核苷酸序列和包含重链和轻链免疫球蛋白分子的氨基酸序列,特别是对应于跨越框架区和/或互补决定区(CDR)的连续重链和轻链序列的序列,特别是从FR1至FR4或CDR1至CDR3 被披露。 还公开了表达这种免疫球蛋白分子和单克隆抗体的杂交瘤或其它细胞系。
-
公开(公告)号:US20120244167A1
公开(公告)日:2012-09-27
申请号:US13458820
申请日:2012-04-27
申请人: Vahe Bedian , Madhav Narasimha Devalaraja , Ian Foltz , Mary Haak-Frendscho , Sirid-Aimée Kellermann , Joseph Edwin Low , James Leslie Mobley
发明人: Vahe Bedian , Madhav Narasimha Devalaraja , Ian Foltz , Mary Haak-Frendscho , Sirid-Aimée Kellermann , Joseph Edwin Low , James Leslie Mobley
IPC分类号: A61K39/395 , A61P29/00 , A61P35/00 , C12N1/19 , A61P9/00 , C12N5/16 , C12N5/10 , C12N1/21 , C07K16/24 , A61P25/00
CPC分类号: C07K16/243 , A61K38/193 , A61K39/395 , A61K2039/505 , C07K16/24 , C07K2317/14 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , G06Q30/02 , G06Q30/0601 , G06Q40/04 , G06Q50/12 , Y02A50/412
摘要: The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to a M-CSF, preferably human M-CSF, and that function to inhibit a M-CSF. The invention also relates to human anti-M-CSF antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-M-CSF antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-M-CSF antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-M-CSF antibodies. The invention also relates to transgenic animals and transgenic plants comprising nucleic acid molecules of the present invention.
摘要翻译: 本发明涉及特异性结合M-CSF,优选人M-CSF的抗体及其抗原结合部分,其功能是抑制M-CSF。 本发明还涉及人抗M-CSF抗体及其抗原结合部分。 本发明还涉及嵌合,双特异性,衍生的单链抗体或融合蛋白的部分的抗体。 本发明还涉及衍生自人抗M-CSF抗体的分离的重链和轻链免疫球蛋白和编码这种免疫球蛋白的核酸分子。 本发明还涉及制备人抗M-CSF抗体的方法,包含这些抗体的组合物和使用该抗体和组合物进行诊断和治疗的方法。 本发明还提供使用编码包含人抗M-CSF抗体的重和/或轻免疫球蛋白分子的核酸分子的基因治疗方法。 本发明还涉及包含本发明的核酸分子的转基因动物和转基因植物。
-
10.
公开(公告)号:US20120195905A1
公开(公告)日:2012-08-02
申请号:US13446637
申请日:2012-04-13
申请人: Vahe Bedian , David Jenkins , Ian FOLTZ
发明人: Vahe Bedian , David Jenkins , Ian FOLTZ
IPC分类号: A61K39/395 , C07K16/18 , A61P35/00 , C12N15/13
CPC分类号: C07K16/28 , A61K39/395 , A61K39/39533 , A61K39/3955 , A61K2039/505 , C07H21/04 , C07K14/475 , C07K16/22 , C07K2317/565 , C07K2317/92
摘要: The invention relates to targeted binding agents against DLL4 and uses of such agents. More specifically, the invention relates to fully human monoclonal antibodies directed to DLL4. The described targeted binding agents are useful in the treatment of diseases associated with the activity and/or overproduction of DLL-4 and as diagnostics.
摘要翻译: 本发明涉及针对DLL4的靶向结合剂及其用途。 更具体地,本发明涉及针对DLL4的完全人单克隆抗体。 所描述的靶向结合剂可用于治疗与DLL-4的活性和/或过量产生相关的疾病和作为诊断。
-
-
-
-
-
-
-
-
-